Search clinical trials for: Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)

Total 107 results

Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Breast Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Beijing Friendship Hospital

Completed

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 Therapy

China
Eye & ENT Hospital of Fudan University

Active, not recruiting

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Chemotherapy | Immunotherapy | Hypopharyngeal Carcinoma

China
Zhejiang University

Recruiting

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Colon Cancer | Neoadjuvant Therapy

China
China Medical University, China

Terminated

A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

Stomach Neoplasms

China
Zhou Fuxiang
Hubei Cancer Hospital; Henan Provincial People's Hospital; Huangshi Central Hospital...

Recruiting

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Pfizer

Completed

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Neoplasms

Poland, United States, Spain
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Medical University

Completed

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

Neoadjuvant Therapy | Advanced Gastric Cancer | Multi-omics Analysis

China
Sun Yat-sen University
Peking University; Zhejiang Cancer Hospital; Xiangya Hospital of Central South... and other collaborators

Not yet recruiting

Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC (NX-NPC)

Nasopharyngeal Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Wan-Guang Zhang

Recruiting

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC (CCGLC-010)

Macrotrabecular Massive Hepatocellular Carcinoma

China
Zhongshan Hospital Xiamen University

Unknown

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Hepatic Metastasis of Colorectal Cancer

China
Peking University People's Hospital
Chinese Sarcoma Study Group

Recruiting

Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma (MAPAC)

Osteosarcoma | Chemotherapy Effect | Survival | Toxicity, Drug

China
Latin American Cooperative Oncology Group
GlaxoSmithKline

Completed

Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. (GLICO-0801)

BRMS1 | Performance Status Zero to Two for Beginning the Study | Patient With a Maximum of One Chemotherapy | Patient With Progression After Taxanes

Argentina, Brazil, Peru
Columbia University

Unknown

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

Pancreatic Cancer Stage III | Pancreatic Cancer Stage II

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Pancreatic Neoplasms

United States
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Harbin Medical University

Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Rectal Cancer
First Affiliated Hospital of Zhejiang University

Not yet recruiting

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Advanced Biliary Tract Carcinoma

China
Medical College of Wisconsin

Active, not recruiting

Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer

Unresectable Pancreatic Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
University of Southern California
Sanofi

Terminated

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

Pancreatic Cancer

United States
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Breast Cancer Metastatic

Taiwan
Eli Lilly and Company

Completed

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Breast Neoplasms

France, Germany, Italy, Netherlands, Spain, United Kingdom
Eli Lilly and Company

Completed

A Phase III Trial For Patients With Metastatic Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer of the Breast

United States, Argentina, Australia, Brazil, Korea, Republic of, Mexico, Puerto Rico, Taiwan
Merrimack Pharmaceuticals

Completed

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

HER-2 Gene Amplification

United States
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Columbia University
Sanofi

Completed

Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)

Metastatic Pancreatic Cancer

United States
Novartis Pharmaceuticals

Completed

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (RIGHT Choice)

Breast Cancer

India, Malaysia, Saudi Arabia, Taiwan, Russian Federation, Lebanon, South Africa, Thailand, Jordan, Turkey, Egypt, Vietnam, Singapore
University of Nebraska
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Sun Yat-sen University

Unknown

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Carcinoma of Unknown Primary

United States
Columbia University

Completed

Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar

Pancreatic Cancer Stage IVA

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
National Cancer Institute, Naples

Terminated

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer (DISTAL-2)

Advanced Non-Small Cell Lung Cancer

Italy
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Asan Medical Center

Completed

Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
The First Hospital of Jilin University

Unknown

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Non Small Cell Lung Cancer

China
Fudan University
Nanfang Hospital of Southern Medical University; Ningbo Medical Center Lihuili... and other collaborators

Recruiting

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Columbia University

Terminated

GTX Regimen for Biliary Cancers

Biliary Cancer

United States
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China

Search clinical trials for: Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations